Osteoporosis Therapeutics - A Global Market Perspective

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.OUTLOOK
3.INDUSTRY OVERVIEW
Osteoporosis Therapeutics: An Evolutionary Scan
"A Sketch of the Present Industry Scenario"
Facts & Figures: The Osteoporosis Primacy
Snapshots
Factors Influencing Demand
Competitive Landscape
Market Trends and Issues
Can New Treatments Beat the Gold Standard?
Oral Calcitonin Likely to Emerge as Wonder Drug
New Bisphosphonates Challenge Established Brands
Side Effects of HRT Fuel Natural Alternatives Sales
Bone Formation Drugs Augur New Prospects
Estrogen Replacement Therapy: Will Dosing Make a Difference?
Is Prevention Always Better Than Cure?
Peptide-Based Osteoporosis Therapy Gaining Ground
Polymorphism- A Potent Diagnostic Marker
Bisphosphonates – The Other Side
Efficacy of Evista Under the Scanner
4.MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE
ERT Drugs
Ups and Downs in the ERT Market
Bisphosphonates
The leading Therapeutic Market
SERMs (Selective Estrogen Receptor Modulators)
Market Overview
Calcitonins
Market Overview
5.PRODUCT FACTS
Bisphosphonates
Hormone Replacement Therapy/ Estrogen Replacement Therapy
Estrogens
Estrogens/Progesterones
Calcitonins
Selective Estrogen Receptor Modulators (SERMs)
Other Therapeutics
6.MAJOR CLINICAL TRIALS/FINDINGS
7.CORPORATE DEVELOPMENTS
Schering-Plough Acquires Organon BioSciences
Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
Alethia and Emerillon Collaborate on Osteoporosis Therapies
Ipsen Enters into Co-marketing Agreement with MSD
Unigene Enters into Agreement with Novartis
Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
Procter & Gamble Terminates Nasal Spray Collaboration with Nastech- Pharmaceutical
GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
Radius Initiates Phase II Trials for BA058
Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
Medivir Initiates First Human Trials for MIV-701
P&G Receives FDA Approval for New Dosage of Actonel
Takeda Introduces Benet® for Osteoporosis Treatment
Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
Merck’s New Dosage of FOSAMAX PLUS D Gains FDA Approval
Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug
8.MAJOR PLAYERS
Eli Lilly and Company (US)
F.Hoffmann-La Roche Ltd (Switzerland)
Merck & Co., Inc. (US)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Organon
Procter & Gamble Pharmaceuticals Inc. (US)
Sanofi-Aventis SA (France)
Servier SA (France)
Solvay Pharmaceuticals Inc. (US)
Unigene Laboratories, Inc. (US)
Wyeth (US)
9.GLOBAL MARKET ANALYTICS
10.THE UNITED STATES
Industry Overview
Osteoporosis in the US: An Insight
Osteoporosis – An Underserved Market?
Osteoporosis Prescription Market
Competitive Scenario
Competitive Review by Segment
Bisphosphonates
SERMs
Calcitonins
PTH Therapy
11.JAPAN
12.EUROPE
a.France
b.Germany
c.The United Kingdom
d.Italy
e.Spain
f.Rest of Europe
13.REST OF WORLD
Prevalence of Osteoporosis in Various Region-At a Glance
Korea
China
Exhibits
Table 1: Prevalence of Osteoporosis and Osteopenia in Major Markets Worldwide – 2008 &
Table 2: Percentage Breakdown of Leading Players in the Global Osteoporosis Market -
Table 3: Leading Osteoporosis Drugs Worldwide by Dollar Sales -
Table 4: Leading Osteoporosis Therapies and its Cost per Day
Table 5: Global Osteoporosis Therapeutics Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 6: Percentage Breakdown of Global Osteoporosis Therapeutics Market by Region for the Years 2008 & 2009
Table 7: Global Bisphosphonates Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 8: Percentage Breakdown of Global Bisphosphonates Market by Region for the Years 2008 & 2009
Table 9: Global ERT Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 10: Percentage Breakdown of Global ERT Drugs Market by Region for the Years 2008 & 2009
Table 11: Global SERM Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 12: Percentage Breakdown of Global SERM Market by Region for the Years 2008 & 2009
Table 13: Global Calcitonins Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 14: Percentage Breakdown of Global Calcitonins Market by Region for the Years 2008 & 2009
Table 15: Market Shares of Leading Osteoporosis Drugs in the US
Table 16: Market Shares of Leading Players in the US Osteoporosis Market –
Table 17: Market Shares of Leading Players in the US Bisphosphonates Market –
Table 18: Osteoporosis Therapeutics Market by Product Group in the US: 2007-2015 (Sales in US$ Million)
Table 19: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in the US for the Years 2008 & 2009
Table 20: Osteoporosis Therapeutics Market by Product Group in Japan: 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Japan for the Years 2008 & 2009
Table 22: Market Shares of Leading Players in the European Market for Osteoporosis Therapeutics (2005)
Table 23: Osteoporosis Therapeutics Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 24: Percentage Breakdown of Osteoporosis Therapeutics Market by Region in Europe for the Years 2008 & 2009
Table 25: Osteoporosis Therapeutics Market by Product Group in Europe: 2007-2015 (Sales in US$ Million)
Table 26: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Europe for the Years 2008 & 2009
Table 27: Osteoporosis Therapeutics Market by Product Group in France: 2007-2015 (Sales in US$ Million)
Table 28: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in France for the Years 2008 & 2009
Table 29: Osteoporosis Therapeutics Market by Product Group in Germany: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Germany for the Years 2008 & 2009
Table 31: Osteoporosis Therapeutics Market by Product Group in The UK: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in The UK for the Years 2008 & 2009
Table 33: Osteoporosis Therapeutics Market by Product Group in Italy: 2007-2015 (Sales in US$ Million)
Table 34: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Italy for the Years 2008 & 2009
Table 35: Osteoporosis Therapeutics Market by Product Group in Spain: 2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Spain for the Years 2008 & 2009
Table 37: Osteoporosis Therapeutics Market by Product Group in Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Rest of Europe for the Years 2008 & 2009
Table 39: Percentage Breakdown of Leading Brands in the Korean Osteoporosis Therapeutics Market -
Table 40: Osteoporosis Therapeutics Market by Product Group in Rest of World: 2007-2015 (Sales in US$ Million)
Table 41: Percentage Breakdown of Osteoporosis Therapeutics Market by Product Group in Rest of World for the Years 2008 & 2009 2012Companies Profiled